Graft Vs Host Disease Clinical Trial
Official title:
Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells
Graft-versus-host disease (GVHD) is a frequent and severe complication of hematopoietic stem
cell transplantation (HSC), and is responsible for significant early mortality despite
prophylactic strategies developed in recent decades, Especially since it is resistant to
first-line treatment.
The present diagnosis is difficult, non-specific and is based on the combination of an
evocative clinical context (CSH allograft, time to appearance before J100, characteristic
clinical manifestations), suggestive anatomo-pathological analysis (predominantly
inflammatory infiltrate Lymphocyte, mucosal edema and presence of apoptotic bodies), and the
exclusion of any differential diagnosis (in particular serology / negative viral PCR).
However, to date there is no molecular characterization of this manifestation, and therefore
no specific treatment.
The nCounter® nanostring technology allows the rapid and simple analysis of the simultaneous
expression of a group of genes (up to 800 on the same sample), from a very small amount of
RNA, and from samples with difficulty Such as fabrics already fixed to formaldehyde and
included in paraffin. It allows the detection of a "molecular signature" of the tissue
analyzed.
No transcriptomic analysis has ever been performed on human tissues with GVHD.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06080490 -
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
|
||
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Withdrawn |
NCT04728646 -
Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes
|
Phase 4 | |
| Suspended |
NCT01972438 -
A Randomized, Controlled, Double-masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01221766 -
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
|
N/A | |
| Recruiting |
NCT01764100 -
Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)
|
Phase 1 | |
| Completed |
NCT00760981 -
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
|
Phase 1 | |
| Terminated |
NCT00298324 -
Myfortic - Treatment for Extensive cGvHD
|
Phase 3 | |
| Completed |
NCT00224874 -
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
|
Phase 2 | |
| Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
| Completed |
NCT00023491 -
Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells
|
N/A | |
| Recruiting |
NCT05111834 -
IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms
|
N/A | |
| Completed |
NCT02841995 -
A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
|
Phase 2 | |
| Recruiting |
NCT06143501 -
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
|
||
| Recruiting |
NCT04622956 -
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Not yet recruiting |
NCT06450925 -
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
|
N/A | |
| Not yet recruiting |
NCT02506231 -
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01042509 -
Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
|
N/A |